The board of Novartis AG ( VTX:NOVN ) has announced that it will be paying its dividend of $3.70 on the 12th of ...

Novartis AG (NVS) reported Q4 2025 results, with net sales up 1% to $13.34B, missing estimates. Generic competition and ...

The average one-year price target for Novartis AG - Depositary Receipt (NYSE:NVS) has been revised to $149.84 / share. This ...

Novartis AG (NYSE:NVS) Q4 2025 Earnings Call Transcript February 4, 2026 Novartis AG beats earnings expectations. Reported EPS is $2.03, expectations were $1.99. Operator: Good morning and good ...

NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, ...

Novartis AG is introducing new technology into its products to reinvent its image. The Switzerland-based drug giant is implementing technology such as Google’s sensors in contact lenses and pills with ...

Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure and drug-discovery ...

Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a ...

Novartis AG (NYSE:NVS) agreed to acquire Regulus Therapeutics Inc. (NASDAQ:RGLS) on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion. The upfront cash portion of the ...

Good morning and good afternoon, and welcome to the Novartis Q4 Full Year 2025 Results Release Conference Call and Live ...